Webinar Panel on Oncology Licensing – “What’s hot and what’s not in oncology licensing”.
SIGN UP HERE.
This panel discussion will be a lively Q&A on what is exciting in cancer drug development and what is not popular in licensing, and why.
Biotech and pharmaceutical consultant Linda Pullan will be joined by three panelists who are business development experts from a global pharmaceutical company, a leading academic cancer center, and a top business development consulting firm. The panelists will discuss theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more.
If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to hear these perspectives.
At the end, you too can ask your questions.
Hear From These Web Panelists:
About Linda Pullan, Ph.D
Pullan Consulting Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience.
About Jeff Bockman, Ph.D
Vice President, Defined Health Jeff leads the Oncology and Virology practices at Defined Health. Previously, he was a Senior Research Scientist in the commercial development of therapeutics for viral diseases and cancer at Innovir Laboratories.
About Paul Juniewicz
Vice President, Oncology Business Opportunities, Sanofi Paul is currently the North American Head of Oncology Business Opportunities (OBO) within the Strategic Portfolio and Management Group of the Oncology Division for Sanofi. Paul is responsible for scouting and evaluating external oncology opportunities and possible research collaborations.
About Ferran Prat, Ph.D
VP of Strategic Industry Ventures, MD Anderson Ferran helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners.